Acupoint Application in Patients with Chronic Stable Angina Pectoris: Study Protocol of a Randomized, Double‐Blind, Controlled Trial

Abstract

Background. Chronic stable angina pectoris (CSAP) is a major syndrome of ischemic heart disease (IHD). CSAP manifests as chest pain or discomfort and affects patients' quality of life. Acupoint application (AP) has been reported to be effective for managing the symptoms of CSAP, but the evidence is not convincing. Therefore, we designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of AP in the treatment of CSAP. Methods and Analysis. Two hundred participants with CSAP will be randomly assigned in a 1 : 1 : 1 : 1 ratio into 4 groups. All participants will receive 12 sessions of treatment in 4 weeks and the same basic treatment procedure. The participants will be visited and assessed for 12 weeks, including a 4-week screening, a 4-week treatment phase, and a 4-week follow-up phase. The primary outcome is the change in the total frequency of self-reported angina attack at 4th week compared with the baseline. The secondary outcomes include the intensity of angina pain, consumption of nitroglycerin or Suxiao Jiuxin pills, CCS angina classification, SAQ, SAS and SDS score. Ethics. The study protocol has been reviewed and approved by the Sichuan Regional Ethics Review Committee on TCM (number 2013kl-001). This trial is registered with clinicaltrials.gov NCT02029118.

Enhancement of Functionality and Therapeutic Efficacy of Cell-Based Therapy Using Mesenchymal Stem Cells for Cardiovascular Disease

“…Another natural product, Suxiao jiuxin pill (SJP), consists of two major components, tetramethylpyrazine (TMP) and borneol (BOR), and is a prominent traditional Chinese medicine used to treat acute ischemic heart disease [ 131 , 132 , 133 ]. SJP has significant effects on oxidative stress and vascular reactivity that may lead to improved blood flow.…”

Effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris

“…[ 12 – 14 ] Increasing clinical researches reported that GLXBBX decoction has been widely used and of great benefit in improving for SAP patients; however, there has been no complete evaluation of the clinical evidence regarding GLXBBX decoction as intervention for SAP in evidence-based medicine. [ 4 , 7 ]…”

Corn silk decoction for blood lipid in patients with angina pectoris: A systematic review and meta‐analysis

“…AP is related to myocardial ischemia by increasing myocardial oxygen demand and reducing diastolic perfusion time, and more than half of the patients with coronary heart disease were suffering from AP (Fihn et al, 2014;Liu, Du, Cong, Jia, & Yang, 2016). Although conventional pharmacotherapy has been widely applied, a substantial proportion of patients still fail to relieve angina-related symptoms completely (Ren et al, 2014;Wee, Burns, & Bett, 2015). Accumulating evidence indicates that dyslipidemia is correlated with atherosclerotic plaque, playing a dominant role in the occurrence and progression of AP.…”